ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.

Daniel A Goldstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.